Research Article
Predicting the Survival Probability of Neuroendocrine Tumor Populations: Developing and Evaluating a New Predictive Nomogram
Table 2
Univariate analysis, 3-year survival rate, and 5-year survival rate.
| | Variable | value | HR (95% CI) | 3-year survival rate (95% CI) | 3-year survival rate (95% CI) |
| | Grade | 0.0063 | 0.65 (0.47-0.88) | | | | G3 (reference) | | | 37.08% (26.86%-51.2%) | 5.06% (1.68%-15.2%) | | G1-2 | | | 44.1% (36.7%-53.1%) | 27.8% (20.6%-37.6%) | | Lymphatic | 0.0096 | 1.5 (1.1-2.1) | | | | No (reference) | | | 48.4% (38.8%-60.5%) | 25.1% (17%-37%) | | Yes | | | 38% (30.11%-47.9%) | 14.3% (8.33%-24.7%) | | Differentiation | 0.003 | 1.3 (1.1−1.5) | | | | High (reference) | | | 45.2% (37.8%-54.1%) | 28.1% (20.9%-37.9%) | | Low | | | 3.94% (24.783%-49.3%) | 3.49% (0.898%-13.7%) | | CEA (ng/mL) | 0.00012 | 1 (1-1) | | | | Normal (<5.0) | | | 38.4% (29.3%-50.4%) | 20.1% (12.3%-33%) | | Abnormal | | | 44.5% (36.4%-54.5%) | 19% (12.6%-28.5%) | | Hemoglobin (g/L) (male) | 0.016 | 1 (1-1) | | | | Normal (120-165) | | | 25.24% (16.5%-38.6%) | 8.41% (3.4%-20.8%) | | Abnormal | | | 62.4% (48.6%-80%) | 38.6% (23.6%-63.2%) | | Hemoglobin (g/L) (Female) | 0.016 | 1 (1-1) | | | | Normal (110-150) | | | 39.7% (28.7%-54.8%) | 16.7% (9%-31%) | | Abnormal | | | 56% (43.3%-72.5%) | 24.7% (13.5%-45.3%) | | Creatinine (μmol/L) | 0.012 | 0.99 (0.98-1) | | | | Male | | | | | | Normal (60–110) | | | 0 | 0 | | Abnormal | | | 40.3% (23.8%-68.4%) | 26.9% (10.3%-70.1%) | | Female | | | | | | Normal (45-90) | | | 0 | 0 | | Abnormal | | | 53.4 % (34.9%-81.8%) | 33.9% (17.3%-66.6%) | | PT(s) | 0.00037 | 0.81 (0.73-0.91) | | | | Normal (12–14) | | | 47.5% (36.9%-61.1) | 33% (22.8%-47.8%) | | Abnormal | | | 38.9% (31.45%-48%) | 12.4% (7.48%-20.7% | | INR | 0.0048 | 0.2 (0.065-0.61) | | | | Normal(0.8 - 1.2) | | | 40.8% (34.2%-48.7%) | 18.9% (13.5%-26.4%) | | Abnormal | | | 49.4 % (32.61%-74.9%) | 21.6% (8.46%-55.3%) | | Total bilirubin (μmol/L) | 0.00055 | 1 (1-1) | | | | Normal (3.4-17.1) | | | 42%(35.4%-50%) | 19.3%(13.8%-27%) | | Abnormal | | | 38.9% (23.79%-63.7%) | 19.5% (8.32%-45.6%) | | AST (U/L) | 0.045 | 1 (1-1) | | | | Normal (8-40) | | | 41% (34.2%-49.1%) | 17.8%(12.5%-25.5%) | | Abnormal | | | 45.4% (31.2%-66%) | 26.5% (13.7%-51.1%) | | Tumor metastasis | 0.023 | 1.2 (1−1.4) | | | | No | | | 52.91% (44.5%-59.1%) | 42.36% (30.2%-48.1%) | | Yes | | | 40.98% (36.8%-48.2%) | 38.25% (32.2%-45.5%) | | Number of tumor metastases | 0.00022 | 1.5 (1.2−1.8) | | | | ≤1 | | | 43.4% (36.9%-51.1%) | 20.3% (14.8%-27.8%) | | >1 | | | 0 | 0 |
|
|
